Randomized, phase II/III study of pegylated liposomal doxorubicin, bevacizumab, and atezolizumab in platinum-resistant ovarian cancer (NRG-GY009): Clinical outcomes by PD-L1 and T cell infiltration status Meeting Abstract
| Authors: | O'Cearbhaill, R.; Zamarin, D.; Sill, M.; Duong, H.; Waggoner, S.; Grisham, R.; Backes, F.; Mannel, R.; Tanyi, J.; Powell, M.; Mathews, C.; Ghamande, S.; McNally, L.; Olawaiye, A.; Bender, D.; Duska, L.; Lankes, H.; Schilder, R.; Bookman, M.; Aghajanian, C. |
| Abstract Title: | Randomized, phase II/III study of pegylated liposomal doxorubicin, bevacizumab, and atezolizumab in platinum-resistant ovarian cancer (NRG-GY009): Clinical outcomes by PD-L1 and T cell infiltration status |
| Meeting Title: | IGCS 2024 Annual Meeting |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 34 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2024 Oct 16-18 |
| Meeting Location: | Dublin, Ireland |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2024-10-01 |
| Start Page: | A11 |
| Language: | English |
| ACCESSION: | WOS:001444792200043 |
| DOI: | 10.1136/ijgc-2024-IGCS.10 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LB005/#1605 -- Source: Wos |
